These findings further supported the critical role of PDA-intrinsic IFN signaling in promoting resistance to CAR T cell-mediated cytotoxicity and highlighted IFN receptor targeting as a potential strategy to improve CAR T cell therapy. Here, IFNA1 is linked to Patent ductus arteriosus.